Home › Myelofibrosis › Maryland
Pag-aaral pangklinika para sa Myelofibrosis sa Maryland
8 pag-aaral para sa Myelofibrosis ang naghahanap ng mga kalahok sa mga site sa Maryland.
Mga Lungsod sa Maryland
Opisyal na teksto ng pag-aaral (English)
Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore
Nagre-recruitMaagang Phase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Set 24, 2026 · NCT06398457A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis
- University of Maryland, Baltimore
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 23, 2026 · NCT04176198A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms
- Johns Hopkins University, Baltimore
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 6, 2026 · NCT07008118Study of INCA036978 in Participants With Myeloproliferative Neoplasms
- John Hopkins Hospital, Baltimore
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Hul 22, 2026 · NCT07441694A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
- Johns Hopkins Hospital, Baltimore
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Abr 17, 2026 · NCT06034002A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia
- Maryland Oncology Hematology - Independent of SCRI/ US Oncology, Columbia
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Peb 12, 2026 · NCT05980806SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Baltimore
- Massive Bio SYNERGY-AI site, Bethesda
- Massive Bio SYNERGY-AI site, Silver Spring
- at 1 pa
Nagre-recruitObservasyonal na pag-aaral
Lahat ng edad · Lahat ng kasarian · Na-update Okt 28, 2025 · NCT03452774Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
- Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore
- The Center for Cancer and Blood Disorders, Bethesda
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 25, 2025 · NCT06479135Mula sa ClinicalTrials.gov, na-kuha noong Okt 1, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.